ATNM Actinium Pharmaceuticals Inc
Price (delayed)
$1.21
Market cap
$37.75M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.27
Enterprise value
-$33.58M
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application
Highlights
The EPS has grown by 31% YoY and by 9% from the previous quarter
The debt has decreased by 26% YoY and by 8% from the previous quarter
ATNM's revenue has dropped by 100% since the previous quarter and by 100% year-on-year
ATNM's gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
Key stats
What are the main financial stats of ATNM
Market
Valuations
Earnings
Shares outstanding
31.2M
Market cap
$37.75M
Enterprise value
-$33.58M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.15
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$42.12M
Net income
-$38.24M
EBIT
-$38.24M
EBITDA
-$37.43M
Free cash flow
-$33.08M
Per share
Balance sheet
Liquidity
EPS
-$1.27
EPS diluted
-$1.27
Free cash flow per share
-$1.1
Book value per share
$1.05
Revenue per share
$0
TBVPS
$2.56
Total assets
$76.9M
Total liabilities
$44.14M
Debt
$1.57M
Equity
$32.76M
Working capital
$66.36M
Debt to equity
0.05
Current ratio
9.14
Quick ratio
8.95
Net debt/EBITDA
1.91
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-45.4%
Return on equity
-96.4%
Return on invested capital
N/A
Return on capital employed
-55.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATNM stock price
How has the Actinium Pharmaceuticals stock price performed over time
Intraday
-3.2%
1 week
5.22%
1 month
-6.92%
1 year
-83.31%
YTD
-3.97%
QTD
-24.84%
Financial performance
How have Actinium Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$42.12M
Net income
-$38.24M
Gross margin
N/A
Net margin
N/A
ATNM's revenue has dropped by 100% since the previous quarter and by 100% year-on-year
ATNM's gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
ATNM's net income is up by 22% year-on-year and by 7% since the previous quarter
The operating income has increased by 19% year-on-year and by 6% since the previous quarter
Growth
What is Actinium Pharmaceuticals's growth rate over time
Valuation
What is Actinium Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.15
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 31% YoY and by 9% from the previous quarter
The price to book (P/B) is 65% lower than the last 4 quarters average of 3.3 and 59% lower than the 5-year quarterly average of 2.8
The equity has declined by 14% since the previous quarter and by 10% year-on-year
ATNM's revenue has dropped by 100% since the previous quarter and by 100% year-on-year
Efficiency
How efficient is Actinium Pharmaceuticals business performance
The company's return on assets rose by 14% YoY and by 5% QoQ
ATNM's return on equity is up by 6% year-on-year and by 4.5% since the previous quarter
Dividends
What is ATNM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATNM.
Financial health
How did Actinium Pharmaceuticals financials performed over time
Actinium Pharmaceuticals's total assets is 74% more than its total liabilities
The quick ratio has decreased by 12% from the previous quarter
Actinium Pharmaceuticals's current ratio has decreased by 11% QoQ
The debt is 95% less than the equity
The debt has decreased by 26% YoY and by 8% from the previous quarter
The company's debt to equity rose by 25% QoQ but it fell by 17% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.